Skip to main navigation Skip to search Skip to main content

Pharmacokinetics of Doxycycline in Alpacas After Intravenous and Subcutaneous Administration

  • José Martínez
  • , Pedro Marín
  • , David A. Egas
  • , Juan Llivi-Marcatoma
  • , José Miguel Mira-Naranjo
  • , Elena Badillo*
  • , María Teresa Yuste
  • , Elisa Escudero*
  • , Juan Sebastián Galecio
  • *Corresponding author for this work
  • University of Murcia
  • Escuela Superior Politécnica de Chimborazo

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background/Objectives: Doxycycline, a tetracycline-class antibiotic, is commonly used across various species to treat infections caused by susceptible bacteria. However, pharmacokinetic data on its use in alpacas remains limited. This study aimed to investigate the pharmacokinetics of doxycycline following intravenous (IV) and subcutaneous (SC) administration in alpacas. Methods: A randomized crossover study (n = 6) was employed, with dosages of 5 mg/kg and 20 mg/kg after intravenous and subcutaneous administration, respectively. Blood samples were collected at predetermined times up to 96 h after both routes of administration. Plasma doxycycline concentrations were determined using validated high-performance liquid chromatography with a UV detector and then analyzed based on non-compartmental pharmacokinetic methods. Results: All alpacas maintained optimal health and general condition throughout the trial period. After intravenous administration, the Vz value (0.90 L/kg) indicated a good distribution of this antibiotic in the alpacas. The maximum concentration value (Cmax) after SC administration of doxycycline was 1.40 µg/mL, reached at 1.92 h. Low bioavailability (F = 36.83%) of doxycycline was observed after SC administration. Conclusions: PK/PD ratios calculated from the pharmacokinetic data obtained, at a dose of 20 mg/kg and SC route of administration, suggest that doxycycline administered every 24 h could be effective against bacterial infections with MICs of 0.125 and 0.5 µg/mL. However, multi-dose and pharmacodynamic studies are needed to further evaluate the efficacy of using doxycycline in alpacas.

Original languageEnglish
Article number247
JournalAntibiotics
Volume14
Issue number3
DOIs
StatePublished - Mar 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • alpacas
  • bioavailability
  • doxycycline
  • pharmacokinetics
  • subcutaneous
  • tetracyclines

Fingerprint

Dive into the research topics of 'Pharmacokinetics of Doxycycline in Alpacas After Intravenous and Subcutaneous Administration'. Together they form a unique fingerprint.

Cite this